Clinical and Translational Radiation Oncology (Jul 2024)

Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol

  • Guus Grimbergen,
  • Hidde Eijkelenkamp,
  • Louk M.W. Snoeren,
  • Rana Bahij,
  • Uffe Bernchou,
  • Erik van der Bijl,
  • Hanne D. Heerkens,
  • Shawn Binda,
  • Sylvia S.W. Ng,
  • Christelle Bouchart,
  • Zelda Paquier,
  • Kerryn Brown,
  • Richard Khor,
  • Robert Chuter,
  • Linnéa Freear,
  • Alex Dunlop,
  • Robert Adam Mitchell,
  • Beth A. Erickson,
  • William A. Hall,
  • Paola Godoy Scripes,
  • Neelam Tyagi,
  • Jeremiah de Leon,
  • Charles Tran,
  • Seungjong Oh,
  • Paul Renz,
  • Andrea Shessel,
  • Edward Taylor,
  • Martijn P.W. Intven,
  • Gert J. Meijer

Journal volume & issue
Vol. 47
p. 100797

Abstract

Read online

Background and purpose: Treatment planning for MR-guided stereotactic body radiotherapy (SBRT) for pancreatic tumors can be challenging, leading to a wide variation of protocols and practices. This study aimed to harmonize treatment planning by developing a consensus planning protocol for MR-guided pancreas SBRT on a 1.5 T MR-Linac. Materials and methods: A consortium was founded of thirteen centers that treat pancreatic tumors on a 1.5 T MR-Linac. A phased planning exercise was conducted in which centers iteratively created treatment plans for two cases of pancreatic cancer. Each phase was followed by a meeting where the instructions for the next phase were determined. After three phases, a consensus protocol was reached. Results: In the benchmarking phase (phase I), substantial variation between the SBRT protocols became apparent (for example, the gross tumor volume (GTV) D99% ranged between 36.8 – 53.7 Gy for case 1, 22.6 – 35.5 Gy for case 2). The next phase involved planning according to the same basic dosimetric objectives, constraints, and planning margins (phase II), which led to a large degree of harmonization (GTV D99% range: 47.9–53.6 Gy for case 1, 33.9–36.6 Gy for case 2). In phase III, the final consensus protocol was formulated in a treatment planning system template and again used for treatment planning. This not only resulted in further dosimetric harmonization (GTV D99% range: 48.2–50.9 Gy for case 1, 33.5–36.0 Gy for case 2) but also in less variation of estimated treatment delivery times. Conclusion: A global consensus protocol has been developed for treatment planning for MR-guided pancreatic SBRT on a 1.5 T MR-Linac. Aside from harmonizing the large variation in the current clinical practice, this protocol can provide a starting point for centers that are planning to treat pancreatic tumors on MR-Linac systems.

Keywords